When would you choose a retrospective design over a prospective design when planning for a PASS as part of a postmarketing commitment?
What have we seen in the PRAC feedback in the past year?
Speaker
Bettina Rillmann
Associate Director, Scientific Affairs PRA Health Sciences, Germany
REMINDER
This is the presenters’ personal opinion and does not necessarily represent true facts, the official views or policy of their organisation, nor the views of Evidence Life Science.